GI CANCERS

Toufic Kachaamy, MD, discusses an upcoming course that teaches the multidisciplinary approach for clinicians who have a hand in treating gastrointestinal cancers.

Nathan Bahary, MD, discussed with Targeted Oncology how the cholangiocarcinoma treatment paradigm has changed and what is on the horizon for treatment and care of patients.

In an interview with Targeted Oncology, Toufic Kachaamy, MD, discussed in detail the role of the gastroenterology community in staging, diagnosing, and managing gastrointestinal malignancies.

A real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.

Patients with gastrointestinal cancers are being enrolled to a phase 1/2 of pelareorep in combination with atezolizumab.

Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

Olaparib and pembrolizumab appear to be a safe and tolerable combination therapy for patients with advanced cholangiocarcinoma.

According to new KEYNOTE-590 study findings, pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer showed clinical benefit.

In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.

In the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer.

Sintilimab treatment in pancreatic cancer shows mixed efficacy results in the phase 3 CISPD3 trial.

In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.

In a phase 3 study, patients with biliary tract cancer who received adjuvant oral fluoropyrimidine derivative S-1 lived longer than patients who underwent surgery.

According to updated findings from a cohort of the KRYSTAL-1 trial adagrasib may be active in previously treated KRAS G12C¬–mutant gastrointestinal tumors.

With an orphan drug designation in tow, MT-601 will soon be investigated in combination with chemotherapy in phase 1 clinical trial.

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Single nucleotide polymorphisms such as NOTCH1, SEMA4D, NLRC5, and IL6R, may be predictive of nivolumab toxicity in advanced gastric cancer.

Results presented during the 2022 Gastrointestinal Cancers Symposium showed that 58.6% of evaluable patients experienced complete regression and fibrosis with no tumor cells.

Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

An overall survival improvement for the combination of durvalumab and tremelimumab has been reported by the HIMALAYA clinical trial lead investigator.

TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.

A study of cinrebafusp alfa is underway to evaluate its safety and efficacy in combination with other therapies in patients with gastric or gastroesophageal junction cancers.

A fast track designation has been granted to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.